Has Danny Sugimoto, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,402 in general payments to Danny Sugimoto, MD across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danny Sugimoto, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danny Sugimoto, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danny Sugimoto, MD

Internal Medicine · Chicago, ILNPI 1679661821

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,313 of the $10,402 with a category attached, or 60.7%. 12 manufacturers reported payments, led by Novo Nordisk AS at 35.1% of the total. Reporting peaked in 2019 at $4,576 and has fallen 81.7% since, to $835 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,402in general payments, 2019–2025

Across 88 payments — averaging $118.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk AS$4K
Novartis$2K
Astrazeneca UK Limited$2K
Boehringer Ingelheim International GmbH$1K
Pfizer$913
Modernatx, Inc.$360
plus $699 from 6 others

$4,166,977in research payments, 2019–2025

Across 2,949 payments — averaging $1413.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$1.1M
Boehringer Ingelheim$495K
Pfizer$326K
Novavax Inc$285K
Amgen$281K
AstraZeneca$262K
plus $1.4M from 14 others

What the payments were for

Travel & lodging$6,31361%
Food & beverage$3,89637%
Education$1942%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk AS	18	$3,650
Novartis	10	$1,807
Astrazeneca UK Limited	7	$1,697
Boehringer Ingelheim International GmbH	11	$1,277
Pfizer	4	$913
Modernatx, Inc.	9	$360
AstraZeneca	8	$260
Novo Nordisk	6	$194
Lilly USA, LLC	9	$141
Lundbeck LLC	4	$80
AbbVie	1	$13
Teva Pharmaceuticals USA, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LEQVIO$933
Ozempic$742
Saxenda$617
Tresiba$575

How this compares

$10,402 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois →

Medicare billing

Part B allowed, 2024

$4,217

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	17	$6,755
Metformin Hcl	31	$461
Losartan Potassium	16	$271
Amlodipine Besylate	28	$258
Simvastatin	16	$224
Glimepiride	12	$154
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	12	$147
Atorvastatin Calcium	12	$104
Alprazolam	15	$79
ClopidogrelClopidogrel Bisulfate	11	$63
Zolpidem Tartrate	19	$58
Hydrochlorothiazide	11	$29

Paid to pharmacies, not to this prescriber.

Other internal medicine in Chicago

Merle DiamondChicago$1.1M
Robert KushnerChicago$516K
Romeo UrsuaChicago$420K
Peter O DonnellChicago$318K
George UrbanChicago$258K
Kristen PallokChicago$256K
George NissanChicago$252K
Luke LaffinChicago$162K
Daniel CatenacciChicago$161K
Hiren ShahChicago$144K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →